Effect of Phenobarbitone on Plasma Apolipoprotein B and Plasma High-Density-Lipoprotein Cholesterol in Normal Subjects

Durrington, PN

doi:10.1042/cs0560501

Cited by 35 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed increase in HDL-c in patients treated with both nevirapine and EFV has been shown to be accompanied by an increase in levels of apo A1 in plasma. 11,27 Favorable dose-dependent increases in levels of HDL-c [28][29][30] and apo A1 31 have also been observed in patients receiving antiepileptic agents. One study suggests that the observed increase in apo A1 mRNA expression in cell lines exposed to phenobarbital is a result of an increase in apo A1 transcription.…”

Section: Discussionmentioning

confidence: 99%

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

Mahungu

Nair

Smith³

et al. 2009

Clin Pharmacol Ther

View full text Add to dashboard Cite

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are associated with a favorable increase in high-density lipoprotein cholesterol (HDL-c) level. Isolated studies have found a direct correlation between efavirenz (EFV) exposure and HDL-c level changes. Here we explore the impact that drug disposition variants associated with EFV exposure have on changes in HDL-c level. Seventy-six patients on first-line EFV-based regimens were genotyped for CYP2B6 516G>T and ABCB1 3435C>T. There was a 37% increase (+0.32 mmol/l, P < 0.001) in mean HDL-c level over 48 weeks, and this was univariately associated with gender (male +0.26 mmol/l, female +0.55 mmol/l; P = 0.03), ABCB1 3435C>T (CC +0.26 mmol/l, CT +0.16 mmol/l, TT +0.54 mmol/l; P(ANOVA) = 0.003) and CYP2B6 516 G>T (GG +0.27 mmol/l, GT +0.29 mmol/l, TT +0.72 mmol/l; P(ANOVA) = 0.08). There was a significant association between the cumulative number of predictive genotypes (CYP2B6 516TT or ABCB1 3435TT) and mean HDL-c level change: (group 0 +0.20 mmol/l, group 1 +0.47 mmol/l, group 2 +1.00 mmol/l; P(ANOVA) < 0.0001). These findings need to be validated in independent cohorts.

show abstract

Section: Discussionmentioning

confidence: 99%

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

Mahungu

Nair

Smith³

et al. 2009

Clin Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…14,16 Equally, our results do not support the HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; VLDL-C = very-low-density lipoprotein cholesterol. 5,7,13,15,18 Reports on the effects of valproic acid on lipid measurements are conflicting. Statistically significant difference with respect to corresponding treatment mean (normal diet): ***P < .05.…”

Section: Discussionmentioning

confidence: 99%

Evolution of Serum Lipids and Lipoprotein (a) Levels in Epileptic Children Treated With Carbamazepine, Valproic Acid, and Phenobarbital

et al. 2006

View full text Add to dashboard Cite

The concentration levels of serum lipids and lipoprotein (a) were measured in 20 children receiving carbamazepine, 25 children receiving valproic acid, and 5 children receiving phenobarbital at the following times: (1) during chronic treatment while eating a normal diet, (2) during chronic treatment while eating a low-fat diet (children treated with carbamazepine and phenobarbital with high levels of total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol), and (3) 3 months after the end of treatment with antiepileptic drugs. Patients during chronic treatment and eating a normal diet revealed significant changes in lipids, but when we reevaluated the groups of children treated with carbamazepine and phenobarbital when they were eating a low-fat diet and reevaluated the three groups of children 3 months after the end of treatment, a complete return to normal of all parameters was observed. These data demonstrate that the changes induced by these drugs are transient, reversible, and influenced by a low-fat diet. (J Child Neurol 2006;21:48-53).

show abstract

“…This may significantly alter drug disposition and serum concentration of sex hormones. In addition, the concentration of plasma HDL-cholesterol and apolipoprotein B rise during treatment with phenobarbitone (Durrington, 1979) or phenytoin (Nikkila et al, 1978). However, these effects are not seen when phenobarbitone is given in low dosage (Perucca et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

“…It has been suggested that the effect of phenobarbitone and phenytoin in raising HDL-cholesterol (Durrington, 1979;Nikkila et al, 1978) is also due to enzyme induction. In patients receiving these enzyme inducers plasma HDL concentrations are proportional to the magnitude of the induction assessed directly by liver cytochrome P-450 content and indirectly by plasma antipyrine clearance rate (Luoma et al, 1982).…”

Section: Introductionmentioning

confidence: 99%

Enzyme induction with rifampicin; lipoproteins and drug binding to alpha 1‐acid glycoprotein.

Feely¹,

Clee²,

Pereira³

et al. 1983

Brit J Clinical Pharma

View full text Add to dashboard Cite

Hepatic enzyme induction has been reported to increase lignocaine binding, alpha 1‐acid glycoprotein concentration and high density lipoprotein (HDL) cholesterol. In eight volunteers treated with rifampicin for 3 weeks there was no significant alteration in these three variables although their antipyrine clearance was significantly increased. In 10 patients with pulmonary tuberculosis treated with rifampicin (mean 5 months) the degree of serum protein binding of lignocaine, alpha 1‐acid glycoprotein and HDL‐cholesterol concentration was not different from that of matched control patients. These results suggest that differential induction of these variables may occur.

show abstract

Effect of Phenobarbitone on Plasma Apolipoprotein B and Plasma High-Density-Lipoprotein Cholesterol in Normal Subjects

Cited by 35 publications

References 6 publications

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

Evolution of Serum Lipids and Lipoprotein (a) Levels in Epileptic Children Treated With Carbamazepine, Valproic Acid, and Phenobarbital

Enzyme induction with rifampicin; lipoproteins and drug binding to alpha 1‐acid glycoprotein.

Contact Info

Product

Resources

About